Arcturus Therapeutics Holdings Inc. — Form 8-K Summary
Business Context and Reporting Period
Arcturus Therapeutics Holdings Inc. filed a Form 8-K dated December 1, 2020, reporting a material amendment to the loan arrangements of its wholly owned subsidiary, Arcturus Therapeutics, Inc. The report was signed on December 7, 2020.
Material Agreement and Financial Position
- Arcturus Therapeutics, Inc. entered into a Fourth Amendment to its Loan and Security Agreement with Western Alliance Bank, originally dated October 12, 2018.
- The amendment permits Arcturus to grant a limited security interest in certain assets to the lender under a previously disclosed Manufacturing Support Agreement with the Economic Development Board of the Republic of Singapore, dated November 7, 2020.
- The filing does not provide the outstanding loan balance, interest rate, maturity, collateral value, liquidity, revenue, profit, cash flow, or other financial metrics.
Changes, Outlook, Risks, and Unusual Items
The principal reported change is the lender’s consent to a limited security interest in specified assets. The filing does not provide financial guidance, operating outlook, management commentary, or quantified risk disclosures. The complete terms of the Fourth Amendment are contained in Exhibit 10.1.
Investor Verification Items
- Review Exhibit 10.1 for the precise assets subject to the permitted security interest and any related conditions or covenants.
- Review the Manufacturing Support Agreement with Singapore’s Economic Development Board, including funding, performance obligations, collateral provisions, and default terms.
- Verify the company’s current debt balance, liquidity, and covenant compliance in subsequent periodic filings.
- Assess whether the amendment affects the priority or availability of collateral under the existing Western Alliance Bank facility.